Electronic crossmatching based on Rh typing: reducing the production of Rh system alloantibody in blood transfusion recipients
10.13303/j.cjbt.issn.1004-549x.2021.03.003
- VernacularTitle:电子配血技术对减少输血患者Rh血型系统同种抗体产生的意义
- Author:
Kaixuan GAO
1
;
Shaoqiang ZHANG
1
;
Yuanming YANG
1
;
Songxia YAN
1
;
Licun WANG
1
;
Zhen ZHAO
1
;
Zhongcui JING
1
;
Haiyan WANG
1
Author Information
1. Department of Blood transfusion, the Affiliated Hospital of Qingdao University, Qingdao 266000, China
- Publication Type:Journal Article
- Keywords:
Rh phenotype;
irregular antibody;
electronic crossmatching
- From:
Chinese Journal of Blood Transfusion
2021;34(3):210-213
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To study the application of electronic crossmatching(E-XM) based on Rh typing aimed at reducing the production of alloantibodies in blood recipients. 【Methods】 A total of 22 528 RhD positive patients, admitted to our hospital from Jan 1, 2018 to Mar 31, 2020, required the specific transfusion of leukocyte-depleted suspension red blood cells. Among which, 21 334 reached the priority level Ⅰ and Ⅱ by E-XM and were set as the control group, and 1 194 reached the priority level Ⅲ and were set as the experimental group. ABO and Rh (D, C, c, E and e antigens) blood group systems were serologically tested both in blood recipients and donors, and Rh phenotype database was established based on the blood transfusion management system. The incidence of irregular antibodies against the exposure of new antigens involved with RBC transfusions in the control group and the experimental group was compared. 【Results】 The proportion of antigen C and e was significantly higher than that of c and E. The frequency of DCCee and DCcEe were the highest, while that of Dccee and DCCEE were extremely low. 85.2% and 9.5% of the patients reached priority level Ⅰ and Ⅱ, respectively, and only 5.3% reached priority level Ⅲ. 6 patients(less than 0.001%) in the control group (n=21 334), developed Rh system alloantibodies after blood transfusion, and 24 patients(2.01%) in the experimental group (n=1194) developed Rh alloantibodies against the exposure of antigens after blood transfusion. There were significant differences between the experimental group and the control group (P<0.01). 【Conclusion】 The application of E-XM could minimize the incidence of Rh irregular antibodies after RBC transfusion in patients, which contributes to the safety in clinical blood transfusion.
